Major players of the Meningococcal Vaccines Market are facing hurdles keeping their production facilities operational due to the paucity of adequate personnel and resources amidst the COVID-19 (Coronavirus) outbreak. Get a first-hand peek into the key drivers and threats to the Meningococcal Vaccines Market to make your company future-ready post the pandemic. Avail our market reports at unbelievable prices to capitalize on opportunities.
Meningococcal Vaccines Market overview
Meningococcal is a bacterial infection that is caused by Neisseria meningitidis and is also known as meningococcal meningitis that targets the brain of the person. There have been many advances in the medical care sector, but these diseases pose a serious threat to the lives of the patients. Meningococcal meningitis can kill the host within a less time frame. As studied, one in ten patients of this disease die and 15% of the surviving patients suffer from serious brain complications.
Meningococcal consists of different types of bacteria that cause this disease in humans. The most common types of bacteria include A, B, C, W, Y and X type. All these bacterias have been seen in Africa, where the condition of Meningococcal is quite critical and there is a continuous research and development for effective Meningococcal vaccines that will be available soon in the coming years.
The global Meningococcal vaccines market showcases the rising cases of this disease with the increasing demand for vaccines. According to the report, almost 10 to 15 in 100 people get affected with meningococcal disease. The escalation in positive result cases and the need for vaccines is boosting its demand in the global market. The Meningococcal vaccines market has risen upto USD 172 million in the year 2019 and the global supply is estimated to be 203 million doses for the forecast period till 2025.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622
Meningococcal Vaccines Market Key Players
- Baxter international
- Pfizer Inc.
- Sanofi S.A.
- Novartis Pharmaceuticals Inc.
- JN-International Medical Corporation
- Serum Institute of India Ltd.
Meningococcal Vaccines Market segmentation
The global Meningococcal vaccines market is a booming market with a lot of investment and developments. Based on the treatment, the global product market can be divided into:
- Meningococcal Conjugate Vaccine
- Subcapsular vaccine
The Meningococcal A Conjugate Vaccine is mostly used in mass campaigns in affected regions of Africa. Since 2010, the demand for such vaccines has been uncertain, based on the national immunization programs that are being adopted based on the country’s effectiveness and readiness to tackle the disease. Moreover, the demand and supply for Subcap MenB vaccines is a desirable combination that will moderate the global product scenario.
By the end-user, the global vaccine market can be split into:
- Research laboratories
- Hospital and clinical
- Academic institutes
Meningococcal Vaccines Market Regional analysis
As seen in a global scenario, China is expected to dominate the market and accounts for almost 35% of the global meningococcal vaccine demand. The Chinese vendors are focusing on meeting the demands for the domestic market and the polysaccharide products account for 84% of China’s demand. During 2016-2018, UNICEF introduced the meningococcal A conjugate vaccine in 26 countries and Ghana was the first country in Africa to receive this vaccination. Currently, the meningococcal vaccine has reached across different regions, in the most remote locations, and has increased in demand and supply in the global market.
Meningococcal Vaccines Industry news
The European Commission has approved RUXIENCE. It is a monoclonal antibody, developed by Pfizer Inc., for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, microscopic polyangiitis, and pemphigus vulgaris. This comprehensive package has been studied and evaluated with efficacy and safety. RUXIENCE is essential for treating certain cancers and other autoimmune conditions.
Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312
Email: [email protected]
NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.